Clinical Trials Logo

Clinical Trial Summary

A multi-center, open phase Ia/Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and preliminary clinical efficacy of BAT7104 injection in patients with advanced malignant tumors.


Clinical Trial Description

This is a multi-center, open, dose-increased and dose-expanded phase I clinical study. About 18-42 patients will be recruited from research centers in China. In the stage of dose increase, the safety, tolerance, pharmacokinetics and preliminary clinical efficacy of BAT7104 injection in patients with advanced malignant tumors were investigated by using accelerated titration and "3+3" dose increase design. During the dose increase test, the appropriate dose was selected according to the previous study data of the extended study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05767060
Study type Interventional
Source Bio-Thera Solutions
Contact Weining Li
Phone 15202417078
Email wnli@bio-thera.com
Status Recruiting
Phase Phase 1
Start date January 20, 2022
Completion date January 20, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05015309 - A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT06022250 - The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor Phase 1
Recruiting NCT06059508 - Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05851092 - Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors Phase 1
Suspended NCT05089461 - A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor Phase 2
Active, not recruiting NCT04296994 - A Study of QL1706 in Subjects With Advanced Malignant Tumor Phase 1
Recruiting NCT05416359 - Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT04954456 - A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies Phase 1
Recruiting NCT04326829 - QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors Phase 2
Recruiting NCT04739111 - An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor Phase 1
Recruiting NCT04975204 - A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors Phase 1
Recruiting NCT05144061 - A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors Phase 1
Recruiting NCT04412564 - A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor Phase 2
Recruiting NCT05198505 - Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors Phase 1
Not yet recruiting NCT05318833 - A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors Phase 1